These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 7902426

  • 1. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.
    Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R.
    J Clin Oncol; 1993 Dec; 11(12):2405-10. PubMed ID: 7902426
    [Abstract] [Full Text] [Related]

  • 2. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
    du Bois A, Lück HJ, Buser K, Meerpohl HG, Sessa C, Klaassen U, Meden H, Bochtler H, Diergarten K.
    Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
    [Abstract] [Full Text] [Related]

  • 3. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ.
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [Abstract] [Full Text] [Related]

  • 4. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

  • 5. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG, Blessing JA, Mayer AR, Homesley HD.
    J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ.
    J Clin Oncol; 1994 Sep; 12(9):1748-53. PubMed ID: 7916038
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Oct; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 9. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
    Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D, Van Glabbeke M, Lacombe D, Pinel MC, Pecorelli S.
    J Clin Oncol; 2000 Mar; 18(6):1193-202. PubMed ID: 10715288
    [Abstract] [Full Text] [Related]

  • 10. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL.
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L, Jovtis SL, Mickiewicz E, Temperley G, Rondinón M, Blajman C, Cóppola FS, Lewi D, Cazap E, Breier S, Fasce H, Fein L, Polera J, Triguboff E, Uranga G, Pasccón G, Luchina AM, Martínez CA, Politi PM, Rubio G, Alvarez AM.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [Abstract] [Full Text] [Related]

  • 12. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
    Oliverio G, Canuti D, Tononi A, Scarpellini M, Panzini I, Galli I, Ravaioli A.
    J Chemother; 1999 Aug; 11(4):301-5. PubMed ID: 10465133
    [Abstract] [Full Text] [Related]

  • 13. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.
    Bruzzone M, Catsafados E, Miglietta L, Amoroso D, Pedulla F, Giannessi PG, Locatelli MC, D'Antona A, Foglia G, Mammoliti S, Turno F, Gentile A, Nicosia F, Luporini G, Ragni N, Boccardo F.
    Oncology; 1996 Aug; 53(5):349-53. PubMed ID: 8784466
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 15. Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
    Guastalla JP, Lhommé C, Dauplat J, Namer M, Bonneterre J, Oberling F, Pouillart P, Fumoleau P, Kerbrat P, Tubiana N.
    Ann Oncol; 1994 Feb; 5 Suppl 6():S33-8. PubMed ID: 7865432
    [Abstract] [Full Text] [Related]

  • 16. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
    Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM.
    Br J Cancer; 1995 Oct; 72(4):1016-9. PubMed ID: 7547214
    [Abstract] [Full Text] [Related]

  • 17. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer.
    Kavanagh JJ, Gershenson DM, Choi H, Lewis L, Patel K, Brown GL, Garcia A, Spriggs DR.
    Int J Gynecol Cancer; 2005 Oct; 15(4):593-600. PubMed ID: 16014111
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
    Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T.
    J Clin Oncol; 2000 Sep; 18(17):3093-100. PubMed ID: 10963637
    [Abstract] [Full Text] [Related]

  • 19. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.
    Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP.
    J Natl Cancer Inst; 1994 Jan 05; 86(1):18-24. PubMed ID: 7505830
    [Abstract] [Full Text] [Related]

  • 20. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F, MITO 11 investigators.
    Lancet Oncol; 2015 May 05; 16(5):561-8. PubMed ID: 25882986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.